| Targeting DDX 3 with a small molecule inhibitor for lung cancer therapy GM Bol, F Vesuna, M Xie, J Zeng, K Aziz, N Gandhi, A Levine, A Irving, ... EMBO molecular medicine 7 (5), 648-669, 2015 | 204 | 2015 |
| DDX3, a potential target for cancer treatment GM Bol, M Xie, V Raman Molecular cancer 14, 1-16, 2015 | 135 | 2015 |
| Expression of the RNA helicase DDX3 and the hypoxia response in breast cancer GM Bol, V Raman, P van der Groep, JF Vermeulen, AH Patel, ... PloS one 8 (5), e63548, 2013 | 71 | 2013 |
| RK-33 radiosensitizes prostate cancer cells by blocking the RNA helicase DDX3 M Xie, F Vesuna, S Tantravedi, GM Bol, MR Heerma van Voss, K Nugent, ... Cancer research 76 (21), 6340-6350, 2016 | 64 | 2016 |
| Novel, Broad spectrum anticancer agents containing the tricyclic 5: 7: 5-fused diimidazodiazepine ring system A Kondaskar, S Kondaskar, R Kumar, JC Fishbein, N Muvarak, ... ACS medicinal chemistry letters 2 (3), 252-256, 2011 | 64 | 2011 |
| Targeting mitochondrial translation by inhibiting DDX3: a novel radiosensitization strategy for cancer treatment MR Heerma van Voss, F Vesuna, GM Bol, J Afzal, S Tantravedi, ... Oncogene 37 (1), 63-74, 2018 | 62 | 2018 |
| Methylation profiles of hereditary and sporadic ovarian cancer GM Bol, KPM Suijkerbuijk, J Bart, M Vooijs, E Van Der Wall, PJ Van Diest Histopathology 57 (3), 363-370, 2010 | 60 | 2010 |
| NZ51, a ring-expanded nucleoside analog, inhibits motility and viability of breast cancer cells by targeting the RNA helicase DDX3 M Xie, F Vesuna, M Botlagunta, GM Bol, A Irving, Y Bergman, ... Oncotarget 6 (30), 29901, 2015 | 51 | 2015 |
| Expression of DDX3 is directly modulated by hypoxia inducible factor-1 alpha in breast epithelial cells M Botlagunta, B Krishnamachary, F Vesuna, PT Winnard Jr, GM Bol, ... PloS one 6 (3), e17563, 2011 | 47 | 2011 |
| Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer MR Heerma van Voss, JD Brilliant, F Vesuna, GM Bol, E van der Wall, ... Medical Oncology 34, 1-8, 2017 | 34 | 2017 |
| Nuclear DDX3 expression predicts poor outcome in colorectal and breast cancer MR Heerma van Voss, F Vesuna, GM Bol, J Meeldijk, A Raman, ... OncoTargets and therapy, 3501-3513, 2017 | 26 | 2017 |
| Fibroblast activation protein identifies Consensus Molecular Subtype 4 in colorectal cancer and allows its detection by 68Ga-FAPI-PET imaging E Strating, E Wassenaar, M Verhagen, P Rauwerdink, S van Schelven, ... British journal of cancer 127 (1), 145-155, 2022 | 25 | 2022 |
| PLGA nanoparticle formulation of RK-33: An RNA helicase inhibitor against DDX3 GM Bol, R Khan, MR Heerma van Voss, S Tantravedi, D Korz, Y Kato, ... Cancer chemotherapy and pharmacology 76, 821-827, 2015 | 13 | 2015 |
| Targeting RNA helicase DDX3 in stem cell maintenance and teratoma formation CL Kerr, GM Bol, F Vesuna, V Raman Genes & Cancer 10 (1-2), 11, 2019 | 12 | 2019 |
| Targeting DDX3 with a small molecule inhibitor for lung cancer therapy. EMBO Mol Med 7: 648–669 GM Bol, F Vesuna, M Xie, J Zeng, K Aziz, N Gandhi, A Levine, A Irving, ... | 7 | 2015 |
| Trends in use and perceptions about triplet chemotherapy plus bevacizumab for metastatic colorectal cancer SC van Nassau, MJ Bond, I Scheerman, J Van Breeschoten, R Kessels, ... JAMA network open 4 (9), e2124766-e2124766, 2021 | 6 | 2021 |
| Epigenetic biomarkers in the diagnosis of ovarian cancer JG Bijron, GM Bol, RHM Verheijen, PJ Van Diest Expert Opinion on Medical Diagnostics 6 (5), 421-438, 2012 | 6 | 2012 |
| Comparison of NTRK fusion detection methods in microsatellite-instability-high metastatic colorectal cancer SJ Schraa, E Stelloo, MM Laclé, JF Swennenhuis, LAA Brosens, ... Virchows Archiv 482 (6), 983-992, 2023 | 5 | 2023 |
| 364P Prevalence, treatment and survival of NTRK gene fusions in microsatellite instable metastatic colorectal cancer patients S Schraa, MM Laclé, K Zwart, EH Gort, M Koopman, W de Leng, G Vink, ... Annals of Oncology 33, S703, 2022 | 4 | 2022 |
| FOLFOX chemotherapy as a cause of ventricular septal rupture after alcohol septal ablation for obstructive hypertrophic cardiomyopathy? M Liebregts, GM Bol, JW Groen, M Lieuw-a-Fa, RH Heijmen, JM ten Berg International Journal of Cardiology 207, 208-210, 2016 | 4 | 2016 |
